GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (FRA:DVL) » Definitions » Valuation Rank

Alliance Pharma (FRA:DVL) Valuation Rank


View and export this data going back to 2018. Start your Free Trial

What is Alliance Pharma Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Alliance Pharma Valuation Rank Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (FRA:DVL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (FRA:DVL) » Definitions » Valuation Rank
Comparable Companies
LSE:AGY LSE:ANCR LSE:BMK LSE:EAH LSE:CEL LSE:VLG LSE:STX LSE:PXS LSE:CHLL AQSE:ANA XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
APH:UK DVL:Germany
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Website
https://www.alliancepharmaceuticals.com
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).